Royal Philips and Ion Beam Applications SA (IBA), the world’s leading provider of proton therapy and radio pharmacy solutions, announced the signing of collaboration to provide advanced diagnostic and therapeutic solutions for the treatment of cancer.
The collaboration will provide more personalized diagnosis and therapy solutions for cancer patients. The agreement will include research and exchange of technologies and solutions to provide access to proton and therapy solutions and enhance oncology care centres across the globe.
The collaboration covers sales, marketing, research and development (R&D) of imaging and therapy solutions in oncology. By merging their respective expertise in therapy and image guidance systems, IBA and Philips will innovate with an integrated vision for more efficient, personalized cancer care. Leveraging high quality imaging and proton therapy offers the potential to increase confidence in the diagnosis and treatment of cancer, reduce short- and long-term side-effects and potentially enhance the quality of life of the patient before, during and after treatment, while reducing the cost of treatment for the healthcare system.
IBA will benefit from Philips diagnostic imaging products offered to oncology care centres, while Philips will leverage IBA proton therapy solutions within its offering for customers in select markets around the world. The commercial collaboration also includes an integrated offering for Molecular Imaging Centres, combining IBA’s expertise in PET radioisotope production centres with Philips imaging and diagnostics expertise.
Gene Saragnese, Executive Vice President and CEO, Imaging Systems, Philips said: "Proton therapy is one of the most exciting technological advancements in the oncology field. We look forward to collaborating with IBA to enhance access to best-in-class technology for both Proton Centres and Molecular Imaging Centres, as well as to accelerate the development of our informed therapy guidance vision in ways that can change the future of care, and improve the quality of life for patients."